De-escalation of treatment for HER2+ breast cancer is a priority, given the increase in cure rates owing in part to improved HER2-targeted therapies. In this regard, the neoadjuvant approach provides the ideal platform to test less-intensive treatment regimens. Here we highlight a study that demonstrated the role of the metabolic response after dual HER2 blockade as a method of selecting patients who are most likely to benefit from chemotherapy-free neoadjuvant therapy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pérez-García, J. M. et al. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet 403, 1649–1659 (2024).
Miglietta, F., Dieci, M. V., Griguolo, G. & Guarneri, V. Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer. Cancer Treat. Rev. 98, 102222 (2021).
Llombart-Cussac, A. et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 18, 545–554 (2017).
Guarneri, V. et al. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. Ann. Oncol. 30, 921–926 (2019).
Tolaney, S. M. et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 24, 273–285 (2023).
Pérez-García, J. M. et al. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol. 22, 858–871 (2021).
van Mackelenbergh, M. T. et al. Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer. J. Clin. Oncol. 41, 2998–3008 (2023).
Squifflet, P. et al. Re-evaluation of pathologic complete response as a surrogate for event-free and overall survival in human epidermal growth factor receptor 2-positive, early breast cancer treated with neoadjuvant therapy including anti-human epidermal growth factor receptor 2 therapy. J. Clin. Oncol. 41, 2988–2997 (2023).
Dieci, M. V. et al. Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial. NPJ Breast Cancer 9, 6 (2023).
Prat, A. et al. HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. J. Natl. Cancer Inst. 112, 46–54 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.V.D. has acted as a consultant and/or advisor of AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead, MSD, Novartis, Pfizer, Roche and Seagen. V.G. has acted as a consultant and/or advisor board membership for AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Exact Sciences, Gilead, Menarini Stemline, Merck Serono, MSD, Novartis, Olema Oncology, Pfizer, and Pierre Fabre, has acted as a speaker for AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead, GSK, Menarini Stemline, Novartis, Roche and Zentiva and has received personal fees for expert testimony from Eli Lilly.
Rights and permissions
About this article
Cite this article
Dieci, M.V., Guarneri, V. Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain. Nat Rev Clin Oncol (2024). https://doi.org/10.1038/s41571-024-00907-w
Published:
DOI: https://doi.org/10.1038/s41571-024-00907-w
